News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EnVivo Pharmaceuticals, Inc. Initiates COGNITIV AD, A Phase 3 Clinical Trial Program Of Encenicline (EVP-6124) In Alzheimer’s Disease


1/22/2014 9:24:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system (CNS) diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (a7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer’s disease (AD). The program is being conducted under a Special Protocol Assessment agreement with the FDA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES